| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Bright Minds Biosciences Inc.$71.91
+0.58 (+0.81%)
D 24Pipeline Score Richly Valued Biotech · Clinical
Market Cap
817.23 M
EPS
-2.44
P/E Ratio
-
Value Trade
58.21 M
8.06 %
Week
-4.44 %
1 Month
-1.89 %
3 Month
45.67 %
6 Month
86.59 %
5 Year
86.59 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
194.64 K
52 Week Range
23.18 - 123.75
% held by Insiders
23.13 %
% held by Institutions
83.32 %
Enterprise Value
595.37 M
Total Shares
9.73 M
Short %
14.41 %
Float Shares
6.63 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Bright Minds Biosciences Inc.
141Total events
3Upcoming
8Tier-1 (high impact)
2021 – 2026Coverage
Upcoming catalysts 2
TBD
T2Trial Initiation
Subscribe to view catalyst details
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 2
TBD
◆Oral PresentationPresentation
Subscribe to view catalyst details
TBD
▼Equity OfferingCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-05-20 | BMB-101 | phase 2 data readout | Phase 2 | — | – | – | – |
2025-05-20 | BMB-101 | phase 2 data readout | Phase 2 | — | – | – | – |
2025-05-20 | BMB-101 | phase 2 data readout | Phase 2 | — | – | – | – |
Drug Pipeline Intelligence
D24
Pipeline Score $28M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 24%
Micro Cap (rank 695 of 913)
Percentile RankBright Minds Biosciences Inc. faces pipeline headwinds (24/100), with $106M risk-adjusted pipeline value, led by BMB-101 in Healthy (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMB-101 Small molecule | Prader-Willi Syndrome | Phase 2 | NCT07266324 | 23% | $106M | NOT YET_RECRUITING | 16 | FAST | C (53) | Mar 1, 2027 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
BMB-101 | Absence Seizures and Developmental and Encephalopathic Epilepsies | Phase 2 | 2026-01-06 | absence seizures reduction: 73.1%; dee seizures reduction: 63.3%; rem sleep increase: 90% Read More | Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DE Read More | |
BMB-101 | Absence Seizures and Developmental and Encephalopathic Epilepsies | Phase 2 | 2026-01-06 | absence seizures reduction: 73.1%; dee seizures reduction: 63.3%; rem sleep increase: 90% Read More | Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DE Read More | |
BMB-101 | Absence Seizures and Developmental and Encephalopathic Epilepsies | Phase 2 | 2026-01-06 | absence seizures reduction: 73.1%; dee seizures reduction: 63.3%; rem sleep increase: 90% Read More | Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DE Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in DRUG
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
DRUG Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
DRUGFiled by newsfilecorp.com BRIGHT MINDS BIOSCIENCES INC. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that the annual general meeting (the " Meeting ") of shareholders (the " Shareholders ") of
Bright Minds Biosciences Inc. has announced the details for its upcoming Annual General Meeting of shareholders set for March 31, 2026. The meeting will include the presentation of the audited financial statements for the fiscal year ending September 30, 2025, along with the appointment of auditors and election of directors. Shareholders will receive proxy materials electronically per the Notice-and-Access model to streamline the process. Additionally, information on how to obtain paper copies of important documents is provided.
Read more →DRUG▼ -5.2%on this newsshared move
Filed by newsfilecorp.com Date
Bright Minds Biosciences Inc. has announced details for its upcoming Annual General Meeting (AGM) scheduled for March 31, 2026, in Vancouver, BC. The record date for both the notice and voting is set for February 10, 2026. The company will not send proxy materials directly to Non-Objecting Beneficial Owners (NOBO) and will also not be paying for delivery to Objecting Beneficial Owners (OBO). Notice and Access (NAA) requirements apply for both beneficial and registered holders.
Read more →DRUGBright Minds Biosciences to Present at Jefferies Global Healthcare Conference New York City
Bright Minds Biosciences, a biotech company dedicated to developing selective 5-HT2 agonists for various CNS disorders, will present at the Jefferies Global Healthcare Conference on June 3, 2026. The event will be accessible via a webcast linked on their website. Additionally, the company has granted stock options to directors and officers, allowing them to purchase a specified number of shares at a pre-set price. This move reflects the company's strategy to incentivize key stakeholders as they advance their innovative treatments.
Read more →DRUGBright Minds Biosciences to Present at Jefferies Global Healthcare Conference
Bright Minds Biosciences, a company specializing in treatments for CNS disorders, will present at the Jefferies Global Healthcare Conference. The presentation will be accessible via their website, with a replay available for 30 days. Additionally, the company has granted stock options to certain directors and officers as part of its share option plan.
Read more →DRUG▲ +11.1%on this newsshared move
Filed by newsfilecorp.com Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the six months ended
Bright Minds Biosciences Inc. released its condensed interim consolidated financial statements for the six months ended March 31, 2026. The report reveals a considerable comprehensive loss of $18,024,945, which is a stark increase from the previous year's loss of $2,900,775. The company has a significant deficit of $64,603,262 since its inception and relies on external financing sources to cover its operating expenses. Despite substantial working capital of $308,460,046, the company faces challenges in achieving profitable operations.
Read more →DRUG▼ -5%on this news
Bright Minds Biosciences to Present at Upcoming Conferences - February 25, 2026
Bright Minds Biosciences, a company specializing in selective 5-HT2 agonists for CNS disorders, announced its participation in upcoming conferences. The company aims to showcase its innovative treatments for conditions like drug-resistant epilepsy and depression. Their focus on breakthrough therapies highlights their commitment to addressing significant medical needs.
Read more →DRUGFiled by newsfilecorp.com Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three months ended
Bright Minds Biosciences Inc. released its condensed interim consolidated financial statements for the three months ended December 31, 2025. The company reported a comprehensive loss of $7,565,318, marking a significant decline from a net income of $49,610 in the same period in 2024. The total liabilities of the company amounted to $1,599,304, while total shareholders' equity reached $89,280,549. With a total deficit of $54,143,635, the company continues to depend on external financing to cover its operating costs.
Read more →DRUGBright Minds Biosciences Announces Closing of US$175 Million Public Offering
Bright Minds Biosciences has successfully closed a public offering, raising $175 million by selling 1,945,000 common shares at $90 each. The proceeds will be allocated to fund clinical trials for various neurological conditions and to initiate phase 1 trials for BMB-105. The offering was managed by notable financial institutions.
Read more →DRUGto the Company's Annual Report on Form 40-F for the fiscal year ended
Bright Minds Biosciences Inc. is proposing to issue and sell 1,945,000 common shares through an underwriting agreement with TD Securities and others. Additionally, the company has granted underwriters the option to purchase an extra 291,750 shares. The offering is supported by a shelf registration statement filed with the SEC, which includes relevant financial details. This move aims to enhance the company's capital and funding capabilities for future initiatives.
Read more →DRUGFiled by newsfilecorp.com BRIGHT MINDS BIOSCIENCES ANNOUNCES CLOSING OF US$175 MILLION PUBLIC OFFERING New York City
Bright Minds Biosciences Inc. has completed a public offering of 1,945,000 common shares, raising gross proceeds of $175 million. The funds will be allocated towards clinical trials for drug candidates targeting absence seizures, developmental and epileptic encephalopathies (DEE), and Prader-Willi Syndrome, alongside additional research initiatives. Jefferies, TD Cowen, Piper Sandler & Co., and Cantor were the joint managers for the offering. Bright Minds focuses on innovative treatments for neurological and psychiatric disorders, aiming to address significant unmet medical needs.
Read more →DRUG▼ -6.2%on this newsshared move
Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock
Bright Minds Biosciences has announced the pricing of a public offering of 1,945,000 common shares at $90.00 each, aiming to raise approximately $175 million. The proceeds are designated for funding clinical trials for various drug candidates, including those addressing absence seizures and Prader-Willi Syndrome. The offering is expected to close on January 9, 2026, pending regulatory conditions. Additionally, the company has terminated a prior equity distribution agreement, reflecting shifts in its financing strategy. This move underscores Bright Minds' commitment to advancing its innovative treatments in the biotech sector.
Read more →DRUGBRIGHT MINDS BIOSCIENCES ANNOUNCES PRICING OF UPSIZED US$175 MILLION PUBLIC OFFERING OF COMMON STOCK New York City
Bright Minds Biosciences Inc. announced the pricing of a public offering of 1,945,000 common shares at $90.00 each, expected to raise about $175 million. The funds will be used for future clinical trials and the initiation of phase 1 trials for its drug candidates. The offering's closing is scheduled for January 9, 2026, pending customary conditions. The company also terminated a previous equity distribution agreement as part of this new funding strategy.
Read more →DRUG▲ +16.5%on this newsshared move
Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026
Bright Minds Biosciences will announce topline results for its Phase 2 trial of BMB-101, aimed at treating drug-resistant Absence Seizures and Developmental and Epileptic Encephalopathy. The announcement is scheduled for January 6, 2026, during a conference call and live webcast. The company focuses on developing selective 5-HT receptor agonists for neurological and psychiatric disorders.
Read more →DRUG▲ +16.5%on this newsshared move
Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)
Bright Minds Biosciences has announced positive topline results from its Phase 2 BREAKTHROUGH clinical trial of BMB-101 in patients with drug-resistant absence seizures and developmental and encephalopathic epilepsies. The study showed a median reduction of 73.1% in absence seizures and 63.3% in major motor seizures, indicating robust efficacy. Safety and tolerability were favorable, with most adverse events being mild or moderate. The company is preparing for global registrational trials and will present more data throughout the year.
Read more →DRUG▲ +16.5%on this newsshared move
Bright Minds Biosciences Announces Launch of US$100 Million Public Offering
Bright Minds Biosciences Inc. has announced the launch of a public offering of common shares, intending to raise US$100 million. The funds will support clinical trials for its drug candidates targeted at conditions like absence seizures and Prader-Willi Syndrome. Additionally, the company plans to initiate phase 1 trials for its compound BMB-105. The offering includes an option for underwriters to purchase more shares, which adds to the potential capital raised.
Read more →DRUG▲ +16.5%on this newsshared move
BRIGHT MINDS BIOSCIENCES ANNOUNCES LAUNCH OF US$100 MILLION PUBLIC OFFERING New York City
Bright Minds Biosciences Inc. has announced the launch of a public offering aimed at raising US$100 million. The capital will support future clinical trials for its drug candidates and initiate phase 1 trials for BMB-105. Jefferies, TD Cowen, Piper Sandler, and Cantor are serving as joint book-running managers for the offering. The company has a strong focus on developing treatments for neurological and psychiatric disorders, leveraging its selective serotonergic agonists platform.
Read more →DRUG▲ +16.5%on this newsshared move
Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DE
Bright Minds Biosciences announced positive topline results from its Phase 2 BREAKTHROUGH clinical trial of BMB-101, which showed significant reductions in seizure frequency among patients with Absence Seizures and Developmental Epilepsies. The study also noted a marked increase in REM sleep while maintaining total sleep duration. The company is now preparing for global registrational trials based on the promising outcomes. Despite some mild adverse events and discontinuations, the overall safety profile was favorable, marking a potential advancement in treatments for drug-resistant epilepsy.
Read more →DRUG▲ +16.5%on this newsshared move
Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday
Bright Minds Biosciences Inc. has announced a conference call and live webcast to present topline results from the Phase 2 trial of BMB-101. This trial targets drug-resistant Absence Seizures and Developmental and Epileptic Encephalopathy. The event is scheduled for January 6, 2026, at 8:00 AM ET. Bright Minds aims to develop innovative treatments for various neurological and psychiatric disorders, leveraging their unique platform of serotonergic agonists.
Read more →DRUG▲ +8.4%on this news
Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting
Bright Minds Biosciences, a biotechnology company specializing in treatments for CNS disorders, will present at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, and at the 2025 American Epilepsy Society Annual Meeting on December 7, 2025. These events offer the company a platform to showcase their advancements in developing selective 5-HT2 agonists targeting drug-resistant epilepsy and depression. Bright Minds seeks to address the high unmet medical needs within these conditions.
Read more →DRUGBright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)
Bright Minds Biosciences has expanded its Scientific Advisory Board by adding four leading experts in Prader-Willi Syndrome (PWS) to support its clinical programs. The company is progressing with its PWS program, having recently announced BMB-105 as a new clinical candidate. The SAB members bring extensive knowledge about PWS and will provide guidance as Bright Minds initiates the NOVA clinical study for BMB-101, focusing on hyperphagia and associated behavioral challenges. These developments offer optimism for addressing significant unmet needs in the management of PWS.
Read more →DRUG▲ +7.6%on this news
Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH
Bright Minds Biosciences has launched a new program targeting Prader-Willi Syndrome (PWS) with the initiation of the NOVA clinical study for BMB-101. The study aims to evaluate the efficacy, safety, and tolerability of BMB-101, a novel treatment designed to address both hyperphagia and neuropsychiatric symptoms associated with PWS. A key opinion leader event is scheduled for November 6, 2025, to discuss the program and its implications.
Read more →DRUG▲ +7.6%on this newsshared move
Filed by newsfilecorp.com FOR IMMEDIATE RELEASE BRIGHT MINDS BIOSCIENCES EXPANDS SCIENTIFIC ADVISORY BOARD TO INCLUDE RENOWNED EXPERTS IN PRADER-WILLI SYNDROME (PWS) -- Tania Markovic MBBS PhD FRACP; Jennifer L. Miller,
Bright Minds Biosciences has expanded its Scientific Advisory Board by adding four experts in Prader-Willi Syndrome (PWS), aiming to bolster its clinical efforts. This move comes as the company prepares to initiate its clinical studies for a new PWS program involving candidate BMB-101. The board members bring extensive experience that is expected to enhance the development of treatments for the condition. The first study will evaluate BMB-101's efficacy in addressing hyperphagia and behavioral issues associated with PWS.
Read more →DRUG▲ +7.6%on this newsshared move
BRIGHT MINDS BIOSCIENCES INITIATES NEW PRADER-WILLI SYNDROME (PWS) PROGRAM; KOL EVENT SCHEDULED FOR NOVEMBER 6TH -- Company will host a webcast at 10am ET on
Bright Minds Biosciences has initiated a new program for Prader-Willi Syndrome (PWS), launching a Phase 2a study for BMB-101 to assess its efficacy, safety, and tolerability. The company aims to address neuropsychiatric symptoms and hyperphagia associated with PWS, utilizing 5-HT2C agonists as a novel mechanism of treatment. A Key Opinion Leaders (KOL) event is scheduled for November 6, 2025, to discuss the program, its implications, and the current challenges of treating PWS. Overall, the developments represent significant steps forward for the company in its pursuit of effective therapies for rare diseases.
Read more →DRUGBright Minds Biosciences to Present at Upcoming Conferences
Bright Minds Biosciences, Inc. announced its participation in upcoming conferences to present its innovative treatments for drug-resistant epilepsy, depression, and other CNS disorders. The company has also granted stock options to its directors and officers, which are exercisable over five years. Bright Minds aims to deliver breakthrough therapies that address significant medical needs.
Read more →DRUGFiled by newsfilecorp.com For Immediate Release Bright Minds Biosciences to Present at Upcoming Conferences New York City
Bright Minds Biosciences, Inc. has announced its participation in two upcoming conferences, aimed at presenting its work in developing selective 5-HT2 agonists for drug-resistant neurological conditions. The company will participate in the Guggenheim Healthcare Innovation Conference on November 12, 2025, and the Jefferies Global Healthcare Conference in London on November 17, 2025. Additionally, they have granted stock options to key personnel, further indicating planned growth and commitment to its research pipeline.
Read more →DRUGBright Minds Biosciences Announces BMB‑201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model
Bright Minds Biosciences announced promising preclinical results for BMB-201, which demonstrated significant efficacy in reducing facial mechanical allodynia in a validated rat model of vascular headache. The compound outperformed sumatriptan at various timepoints, indicating its potential as a treatment for headache and migraine-related conditions. The results support the advancement of BMB-201 into clinical development.
Read more →DRUGBright Minds Biosciences Announces BMB 201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model New York, New York
Bright Minds Biosciences announced that its investigational compound BMB 201 outperformed sumatriptan in preclinical trials using a validated vascular headache model. The study showed significant reductions in facial mechanical allodynia and greater effect sizes compared to sumatriptan across multiple timepoints. Management indicated that these promising results validate the potential of 5-HT2 agonists for pain management, with plans to advance BMB 201 toward clinical development for headache and migraine conditions. The compound is designed to provide analgesic benefits while minimizing side effects associated with 5-HT2A activation.
Read more →DRUG▼ -5.1%on this news
Bright Minds Biosciences to Present at Upcoming Conferences
Bright Minds Biosciences, a biotechnology firm, has announced its participation in several upcoming conferences, showcasing its focus on developing selective 5-HT2 agonists for drug-resistant epilepsy and other CNS disorders. Key events include the 36th International Epilepsy Congress in Lisbon and the Cantor Global Healthcare Conference. The company's innovative approach to treating neurological and psychiatric conditions is highlighted by its advanced pipeline of therapies. Bright Minds aims to deliver breakthrough treatments that can significantly improve patient lives.
Read more →DRUGFiled by newsfilecorp.com Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the nine months ended
Bright Minds Biosciences Inc. has released its condensed interim consolidated financial statements for the nine months ending June 30, 2025, reporting significant financial losses. The company experienced a comprehensive loss of $8,143,745, a substantial increase compared to the prior year's loss of $2,028,505. Its total liabilities and shareholders' equity show a marked deficit of $42,492,714, indicating ongoing financial challenges and the need for external financing to support operations.
Read more →DRUGBright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
Bright Minds Biosciences will present at the 2025 Jefferies Global Healthcare Conference in New York City. CEO Ian McDonald and CSO Jan Torleif Pedersen will represent the company, which specializes in developing selective 5-HT2 agonists for drug-resistant epilepsy and other CNS disorders. The presentation will be accessible via a live and archived webcast.
Read more →DRUGBright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference New York and Vancouver, BC
Bright Minds Biosciences has announced its participation in the 2025 Jefferies Global Healthcare Conference in New York, with CEO Ian McDonald and CSO Jan Torleif Pedersen set to present. The conference is scheduled for June 5, 2025, and aims to highlight the company's advancements in developing therapies for drug-resistant epilepsy and depression. The event offers a platform for networking and discussions on their novel approaches to CNS disorders. Interested parties can access the webcast via the company's website.
Read more →DRUGBright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025
Bright Minds Biosciences has announced the featured speakers for its virtual R&D Day on May 20, 2025, focusing on Absence epilepsy. Key Opinion Leaders will discuss the impact of Absence seizures and the need for new treatments. The event will also cover the company's BMB-101 study, aimed at treating classic Absence Epilepsy.
Read more →DRUGBright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on
Bright Minds Biosciences Inc. announced the featured speakers for its Absence Epilepsy Virtual R&D Day scheduled for May 20, 2025. Key Opinion Leaders in the field, including Dennis Dlugos, Wendyl D'Souza, and Alexander Rotenberg, will provide insights into Absence seizures and the need for new treatments. The company's leadership team will present the therapeutic rationale for its candidate drug BMB-101 and discuss ongoing Phase 2 clinical trials. A live webinar will be available, with the opportunity for attendees to engage with the speakers.
Read more →DRUGBright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101
Bright Minds Biosciences announced positive findings from its DBA/2 mouse model study, where BMB-101 completely eliminated drop attacks. This novel 5-HT2CGq-protein biased agonist showed 100% survival and reversed serotonin deficits, indicating its potential in preventing sudden unexpected death in epilepsy (SUDEP). The findings support further investigation into BMB-101's efficacy for drug-resistant epilepsy.
Read more →DRUGBright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101 BMB-101 demonstrated a complete elimination of drop attacks in the DBA/2 mouse m
Bright Minds Biosciences reported positive findings from its DBA/2 mouse model study of BMB-101, demonstrating a complete elimination of drop attacks, which is significant for understanding its potential in treating epilepsy. BMB-101 also showed a 100% survival rate in this model, reversing serotonin deficits and preventing seizure-induced respiratory arrest. This investigation indicates the drug's promise in addressing sudden unexpected death in epilepsy (SUDEP), a major concern for drug-resistant epilepsy patients. BMB-101's unique mechanism may provide sustained relief in challenging patient populations, paving the way for further research and clinical applications.
Read more →DRUGBright Minds Biosciences to Host Virtual R&D Day on
Bright Minds Biosciences Inc. announced a virtual R&D Day scheduled for May 20, 2025, focusing on absence seizures and the BMB-101 Phase 2 study. The event aims to address the unmet needs in treating epilepsy, featuring experts in the field. Attendees will have the opportunity to engage with presentations and ask questions. The company's ongoing developments emphasize their commitment to innovative treatments within neurology and psychiatry.
Read more →DRUGBright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study
Bright Minds Biosciences will host a virtual R&D Day on May 20, 2025, focusing on absence seizures and the BMB-101 Phase 2 study. The event will feature presentations from key opinion leaders in epilepsy research, highlighting the unmet needs in this patient group. Attendees will have the opportunity to engage with experts during a Q&A session.
Read more →DRUG▼ -7.7%on this news
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research
Bright Minds Biosciences has expanded its Scientific Advisory Board by adding five leading experts in epilepsy research. This move aims to bolster the company's clinical focus on epilepsy, particularly in the ongoing Phase 2 BREAKTHROUGH study of BMB-101. The new members bring extensive experience in epilepsy drug development, enhancing the company's efforts to address the needs of patients with drug-resistant epilepsy.
Read more →DRUG▼ -7.7%on this newsshared move
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research -- Dennis Dlugos, MD, MSCE; Jacqueline French, MD; Terrence O'Brien, MD; Jo S
Bright Minds Biosciences has expanded its Scientific Advisory Board to include five renowned experts in epilepsy research, which aligns with the company's commitment to focus on drug-resistant epilepsy. These experts bring extensive experience in clinical trials and epilepsy treatments, and their insights are anticipated to shape the direction of the company's clinical programs. The addition of these researchers is particularly timely as Bright Minds advances its Phase 2 BREAKTHROUGH study for BMB-101, aimed at treating adult patients with epilepsy. This strategic move continues to position Bright Minds as a leader in developing innovative therapies for neurological disorders.
Read more →DRUGBright Minds Biosciences to Participate at Three Healthcare Conferences in March
Bright Minds Biosciences will participate in three key healthcare conferences in March 2025. CEO Ian McDonald and senior management will attend the TD Cowen Annual Health Care Conference, the Leerink Partners Global Healthcare Conference, and BIO-Europe Spring. These events aim to enhance the company's visibility and showcase its innovative treatments for CNS disorders.
Read more →DRUGBright Minds Biosciences to Participate at Three Healthcare Conferences in March New York and Vancouver, BC
Bright Minds Biosciences, Inc. announced its participation in three healthcare conferences in March 2025, demonstrating its engagement with the medical community. The company, which specializes in developing selective 5-HT2 agonists for treating drug-resistant CNS disorders, will have its CEO and senior management represent it at these key events. The conferences include the TD Cowen Annual Healthcare Conference, the Leerink Partners Global Healthcare Conference, and BIO-Europe Spring. These appearances are expected to enhance the company's visibility within the biotechnology sector.
Read more →DRUGBright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
Bright Minds Biosciences has appointed Dr. Stephen Collins as its new Chief Medical Officer, effective immediately. Dr. Collins brings extensive experience in drug development, particularly in the central nervous system field, which aligns with Bright Minds’ focus on innovative treatments for epilepsy, depression, and other CNS disorders. His arrival coincides with the initiation of the BREAKTHROUGH Study, a Phase 2 clinical trial assessing the safety and efficacy of the drug BMB-101 in adult patients with specific types of epilepsy. The company is optimistic about advancing its pipeline under his leadership.
Read more →DRUGBright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer -- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- New York
Bright Minds Biosciences has appointed Dr. Stephen Collins as its new Chief Medical Officer, effective immediately. Dr. Collins brings significant expertise in drug development and a focus on epilepsy, which aligns with the company's mission to create new treatments for central nervous system disorders. The company is now directing its efforts toward the ongoing BREAKTHROUGH Study, evaluating the safety and efficacy of BMB-101 for treating epilepsy. Meanwhile, Mark A. Smith will retire from his role as Acting CMO but will remain as an advisor.
Read more →DRUGFiled by newsfilecorp.com For Immediate Release Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting - Poster presentations on BMB-101 will focus on 5-HT 2C functional selectivity
Bright Minds Biosciences Inc. will present data on BMB-101 at the American Epilepsy Society 2024 Annual Meeting, showcasing its Phase 1 clinical findings. The presentations will focus on the 5-HT2C functional selectivity of BMB-101, designed as a novel treatment for drug-resistant epilepsy. Initial results indicate that BMB-101 is safe and well tolerated in healthy volunteers, with a unique mechanism that could mitigate tolerance and improve seizure management. The company also recently initiated a Phase 2 clinical trial to further evaluate BMB-101's efficacy in specific epilepsy patient populations.
Read more →DRUGBright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
Bright Minds Biosciences Inc. will present new data on its epilepsy treatment candidate, BMB-101, at the American Epilepsy Society 2024 Annual Meeting. The presentations will showcase findings from Phase 1 clinical studies, highlighting the safety and tolerability of BMB-101. The drug utilizes a novel mechanism designed to address tolerance issues in chronic treatment of neurological disorders. This research may pave the way for improved management of drug-resistant epilepsy and other CNS disorders.
Read more →DRUG▲ +5%on this news
Filed by newsfilecorp.com BRIGHT MINDS BIOSCIENCES CLOSES US$35 MILLION NON-BROKERED PRIVATE PLACEMENT Vancouver, British Columbia
Bright Minds Biosciences Inc. has successfully completed a non-brokered private placement, raising $35 million through the issuance of 1,612,902 common shares. The offering saw participation from various prominent healthcare investors, which reflects investor confidence in the company’s drug development pipeline targeting neurological and psychiatric conditions. The proceeds will be used to enhance the company's R&D efforts and general working capital. However, the deal involved certain insiders, categorizing it as a related party transaction, and the issued shares are subject to a hold period under Canadian laws.
Read more →DRUG▲ +5%on this news
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
Bright Minds Biosciences has successfully closed a US$35 million non-brokered private placement, issuing 1,612,902 common shares at USD$21.70 each. The proceeds from the offering will be directed towards the company's research and development efforts, particularly for treatments targeting neurological and psychiatric disorders. Significant investment came from recognized firms and insiders, indicating strong support for the company's initiatives. All securities issued are subject to a four-month hold period as per Canadian securities laws.
Read more →DRUGBright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of E
Bright Minds Biosciences has announced a collaboration with Firefly Neuroscience to analyze EEG data from its BREAKTHROUGH Phase 2 trial of BMB-101, a selective 5-HT2C receptor agonist. The study targets adult patients with Absence Epilepsy and Developmental Epileptic Encephalopathy, conditions that are often resistant to existing treatments. Previous collaborations between the two companies have yielded favorable outcomes, and both parties anticipate that the insights gained from this analysis will enhance understanding of BMB-101's efficacy and safety. BMB-101 is positioned as a potentially best-in-class treatment for patients with these challenging neurological disorders.
Read more →DRUGBright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
Bright Minds Biosciences has announced a collaboration with Firefly Neuroscience to analyze EEG data from its BREAKTHROUGH Phase 2 clinical trial of BMB-101, aimed at treating Absence Epilepsy and Developmental Epileptic Encephalopathy. The trial is expected to include 20 adult participants and is designed to assess BMB-101's safety, tolerability, and efficacy in a challenging patient population. Previous collaborations have provided confidence in the analytical capabilities of Firefly's AI technology. BMB-101 is a novel 5-HT2C receptor agonist that offers potential benefits for patients resistant to existing epilepsy treatments.
Read more →DRUG▲ +117.6%on this newsshared move
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES BRIGHT MINDS BIOSCIENCES AN
Bright Minds Biosciences Inc. has announced a non-brokered private placement, aiming to raise up to $35 million through the issuance of common shares and pre-funded warrants. The financing will support the company’s research and development initiatives. Notably, the securities issued will not be available for sale to U.S. persons unless registered or exempted from registration requirements. The announcement highlights both the potential for growth and the inherent risks involved in the offering.
Read more →DRUG▲ +117.6%on this newsshared move
Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement
Bright Minds Biosciences Inc. has announced a non-brokered private placement totaling up to USD$35 million through common shares and pre-funded warrants. The funds are intended for research and development related to the company's drug development programs focused on neurological and psychiatric disorders. The offerings are subject to specific regulatory restrictions and a hold period, which could impact immediate trading. Bright Minds emphasizes its portfolio of novel therapeutic compounds aimed at conditions with high unmet medical needs.
Read more →DRUG▼ -25.2%on this news· ran to -44% by day 1shared move
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
Bright Minds Biosciences announced positive preclinical results for BMB-201, a 5-HT2C/2A mixed agonist, which showed similar efficacy to morphine in pain models, including notable improvements in pain relief and pain-related behaviors. The study aimed to evaluate BMB-201's effectiveness compared to conventional treatments and highlighted its potential as a non-opioid alternative for managing neuropathic pain. With the encouraging data, the company plans to advance BMB-201 into clinical trials to assess its safety and efficacy in humans further.
Read more →DRUG▲ +1445.8%on this news· ran to +1796% by day 3shared move
UNAWARE OF ANY MATERIAL CHANGES Vancouver, British Columbia
Bright Minds Biosciences Inc. has stated that it is unaware of any material changes in its operations that could explain the recent increase in market activity. The company specializes in developing innovative treatments for neuropsychiatric disorders, including treatment-resistant epilepsy and depression, using next-generation serotonin agonists. Bright Minds' goal is to create effective therapeutics while limiting side effects common in older compounds.
Read more →DRUGBright Minds Biosciences announces participation in upcoming scientific conferences and partnering events
Bright Minds Biosciences Inc. announced its participation in several upcoming scientific conferences, including the Neuroscience 2024 and BIO-Europe events. The company aims to present its innovative programs, particularly focusing on BMB-101, a selective agonist for treating drug-resistant epilepsy. The company reported positive outcomes from Phase 1 studies of BMB-101, indicating its safety and potential efficacy. Additionally, Bright Minds has granted stock options to employees as part of its incentive plan, aiming to promote long-term growth.
Read more →DRUGBright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th
Bright Minds Biosciences will host a Key Opinion Leader event on September 25th to discuss their Phase 2 clinical trial of BMB-101 for drug-resistant epilepsies. Renowned epilepsy experts will provide insights into the unmet treatment needs and highlight the potential of BMB-101, which uniquely engages therapeutic pathways without receptor desensitization. The drug has shown promise in preclinical trials and carries the hope of transformed care for epilepsy patients. Registration for the event is required to attend live or access the replay.
Read more →DRUGBright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy Bright Minds Biosciences announces Phase 2 Clinical trial to evaluate BMB-101 in a group of drug-resistant epilepsy disorders with high unmet needs...
Bright Minds Biosciences has launched the BREAKTHROUGH Study, a Phase 2 clinical trial for BMB-101, targeting Absence Epilepsy and Developmental Epileptic Encephalopathy. The trial aims to evaluate the safety and efficacy of BMB-101, a selective 5-HT2C receptor agonist, in patients with drug-resistant epilepsy. The study will enroll 20 adult participants and includes a follow-up period to assess lasting effects.
Read more →DRUGBright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy Bright Minds Biosciences announces Phase 2 Clinical trial
Bright Minds Biosciences has commenced the BREAKTHROUGH Study, a Phase 2 clinical trial aimed at assessing the efficacy and safety of BMB-101 for treating Absence Epilepsy and Developmental Epileptic Encephalopathy. The trial will involve 20 adult participants and consists of various phases to capture detailed efficacy and safety data. BMB-101, a selective 5-HT2C receptor agonist, is designed for chronic treatment and may offer new hope for patients with high unmet medical needs in the epilepsy community. The company has noted its financial stability through 2026, allowing for continued development of this innovative therapy.
Read more →DRUGFiled by newsfilecorp.com 510 Burrard St, 3rd Floor Vancouver BC, V6C 3B9 www.computershare.com Date
Bright Minds Biosciences Inc. has announced details regarding its upcoming Annual General Meeting. The meeting is scheduled for March 22, 2024, with a record date for notice and voting set for February 5, 2024. The meeting will take place in Vancouver, BC, and pertains to the company’s security holders. The issuer will not send proxy materials directly to NOBO, nor will it pay for delivery to OBO.
Read more →DRUGBright Minds Announces Closing of Non-Brokered Private Placement Fully Subscribed by Management Vancouver, British Columbia
Bright Minds Biosciences Inc. announced the closing of a fully management-subscribed, non-brokered private placement, raising $900,000. The funds are intended to support the Phase 2 Clinical Trial for BMB-101, aimed at treating pediatric epilepsy. All units were fully subscribed by CEO Ian McDonald, illustrating strong internal belief in the company’s prospects. The offering comprises common shares and warrants, with no restrictions on securities under Canadian law.
Read more →DRUG▲ +5.5%on this news
Filed by newsfilecorp.com NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES Bright Minds A
Bright Minds Biosciences Inc. has announced a fully subscribed non-brokered private placement managed by its own executives, aiming to raise up to $900,000. This funding intends to support the ongoing Phase 2 Clinical Trial for its treatment candidate BMB-101, targeted at pediatric epilepsy. CEO Ian McDonald is set to subscribe to 100% of the units, demonstrating strong management commitment to advancing the drug's development. The offering is expected to close around December 22, 2023, without any hold period under Canadian securities laws.
Read more →DRUG▲ +9.5%on this news
Filed by newsfilecorp.com Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three and nine months ended
Bright Minds Biosciences Inc. released its financial statements for the three and nine months ending June 30, 2023. The company reported a net loss of $5.84 million and a substantial deficit of $30 million since its inception. Bright Minds has seen a decrease in its cash reserves and operating cash flows, which raises concerns regarding its ongoing financial viability. The report highlights the necessity for the company to secure further financing to cover operational costs and continue its activities.
Read more →DRUG▲ +29.5%on this news
Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101
Bright Minds Biosciences announced positive results from the qEEG data of its Phase 1 study for BMB-101, aimed at treating refractory epilepsies and neuropsychiatric disorders. The study demonstrated BMB-101's excellent safety profile and central target engagement, with notable changes in qEEG indicative of its efficacy. The results indicate a promising path forward for BMB-101, validating its potential as a novel treatment approach. The company plans to host a webcast to discuss these findings, showcasing its commitment to advancing this promising product candidate into Phase 2 trials.
Read more →DRUG▲ +29.5%on this news
Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101 -- BMB-101 is a highly selectiv
Bright Minds Biosciences has reported positive results from the qEEG data in its first-in-human Phase 1 study of BMB-101, a 5-HT2C agonist targeting refractory epilepsies and neuropsychiatric disorders. The trial demonstrated significant safety, tolerability, and target engagement, with notable increases in central delta power. The findings position BMB-101 as ready for Phase 2 studies, indicating its potential to be a transformative treatment in the field. The study was conducted in Adelaide, Australia and highlighted the drug's predictable pharmacokinetics and efficacy in brain receptor activation.
Read more →DRUG▼ -16.4%on this news
Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101
Bright Minds Biosciences has announced positive results from its Phase 1 study of BMB-101, a 5-HT2C agonist targeted at refractory epilepsies and other disorders. The study demonstrated a strong safety and tolerability profile, along with central target engagement, paving the way for future Phase 2 trials. This progress marks a significant step for the company as it transitions from drug discovery to drug development. BMB-101 is now poised for further development, including potential formulation for once-a-day dosing.
Read more →DRUG▼ -16.4%on this news
Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101 -- BMB-101 is a highly selective and potent 5-HT 2C agonist being
Bright Minds Biosciences announced positive topline data from its Phase 1 study of BMB-101, a selective 5-HT2C agonist designed for treating refractory epilepsies and other disorders. The study demonstrated excellent safety, tolerability, and pharmacokinetics in healthy volunteers, marking a significant milestone for the compound. Based on the results, the company aims to advance to Phase 2 trials, addressing unmet needs in neuropsychiatric treatments. Further details will be shared once additional data becomes available.
Read more →DRUGBright Minds Announces Effective Date of Share Consolidation
Bright Minds Biosciences Inc. announced an effective date for its share consolidation on a five-to-one basis, set to begin trading on July 14, 2023. The consolidation aims to strengthen the company’s stock as it continues to develop novel drugs for neuropsychiatric disorders. Shareholders will need to exchange their pre-consolidation shares for post-consolidation equivalents through the company’s transfer agent. Forward-looking statements highlight potential risks regarding future performance.
Read more →DRUGBright Minds Announces Effective Date of Share Consolidation Vancouver, British Columbia
Bright Minds Biosciences Inc. has announced the effective date for its share consolidation, which is set to occur on a five-to-one basis. The consolidated shares will begin trading on both the Canadian Securities Exchange and NASDAQ on July 14, 2023. The company aims to enhance its stock structure through this consolidation, while maintaining its trading symbol and company name. Registered shareholders will need to follow specific instructions for submitting their pre-consolidation shares to receive their new post-consolidation shares.
Read more →DRUG▲ +5.3%on this news
Bright Minds Announces Proposed Share Consolidation
Bright Minds Biosciences Inc. announced its intention to consolidate common shares on a five-to-one basis, aiming to enhance its appeal to investors and regain compliance with NASDAQ listing rules. Currently, the company has approximately 18.9 million shares outstanding, which will reduce to about 3.8 million post-consolidation. The move requires acceptance from the Canadian Securities Exchange, necessitating a future announcement on the effective date of the consolidation. Despite this, the company maintains a focus on developing new treatments for various neuropsychiatric conditions.
Read more →DRUG▲ +5.3%on this news
Bright Minds Announces Proposed Share Consolidation Vancouver, British Columbia
Bright Minds Biosciences Inc. announced its proposal to consolidate shares on a 5-to-1 basis, aiming to increase attractiveness to investors and regain compliance with Nasdaq's minimum bid requirements. Currently, the company has approximately 18.86 million shares, which will reduce to around 3.77 million post-consolidation. This decision reflects their commitment to advancing drug development for neuropsychiatric disorders. The consolidation is pending acceptance from the Canadian Securities Exchange.
Read more →DRUGFiled by newsfilecorp.com Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three and six months ended
Bright Minds Biosciences Inc. released its condensed interim consolidated financial statements for the three and six months ended March 31, 2023. The company reported a net loss of $4,385,927 for the six-month period, contributing to a total deficit of $28,560,725 since inception. With cash and cash equivalents decreasing to $9,672,160, Bright Minds continues to rely on financing to sustain its operations. Shareholders' equity stands at $8,946,482 as of March 31, 2023.
Read more →DRUG▲ +26.1%on this news
Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202
Bright Minds Biosciences has received a favorable Written Opinion from the International Searching Authority for its drug candidate BMB-202, a selective 5-HT2A agonist. This opinion highlights the novelty and inventiveness of its phenethylamine compounds and supports the patenting process. While the opinion is seen as encouraging, it remains non-binding, and the company acknowledges potential risks associated with future clinical trials and regulatory approvals for BMB-202 and its other drug candidates. The company aims to enhance treatment options for neuropsychiatric disorders, epilepsy, and pain.
Read more →DRUG▲ +26.1%on this news
Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202 -- BMB-202 is a highly selective 5-HT 2A agonist that exhibits a mor
Bright Minds Biosciences has received a favorable Written Opinion from the International Searching Authority regarding its drug candidate BMB-202, a highly selective 5-HT2A agonist. This opinion suggests that the core phenethylamine compounds are novel and inventive. BMB-202 demonstrates over 30-fold selectivity over 5-HT2C and over 500-fold over 5-HT2B, with potential applications in treating neuropsychiatric disorders. The development aligns with the company's goal of creating advanced therapies while minimizing side effects compared to existing first-generation psychedelics.
Read more →DRUGBright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research
Bright Minds Biosciences, a biotechnology company, announced that their Scientific Officer, Alex Vasilkevich, will present their work on BMB-101 at the 20th ISSR meeting. BMB-101, a selective 5-HT2C agonist, is currently undergoing a Phase I trial in Adelaide, Australia, to evaluate its safety and efficacy. The presentation aims to engage with leading scientists and share insights into the compound's promising therapeutic potential for treating mental health disorders related to serotonin dysfunction. The company aims to revolutionize treatments for neuropsychiatric disorders and epilepsy.
Read more →DRUG▼ -10.5%on this news
Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023
Bright Minds Biosciences has announced updates on its clinical programs, highlighting the ongoing Phase 1 trial for its lead product, BMB-101, a selective 5-HT2C agonist in Australia. The trial aims to evaluate its safety and tolerability, with results expected in 2Q 2023. Additionally, the company is preparing to enter first-in-human trials for a 5-HT2A agonist later this year. Recent leadership appointments aim to strengthen the company's development organization as it pursues innovative treatments for neuropsychiatric disorders and epilepsy.
Read more →DRUG▼ -10.5%on this news
Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023 -- First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT 2C agonist, is under
Bright Minds Biosciences has provided updates on its clinical programs and outlined anticipated milestones for 2023. The company is currently conducting a first-in-human Phase 1 trial of its lead program, BMB-101, a selective 5-HT2C agonist, in Australia. Key milestones include completed parts of the trial demonstrating safety and tolerability, along with promising drug production activities. The company also announced the appointment of several new leaders to enhance its clinical development capabilities.
Read more →DRUGBright Minds Biosciences Announces Non-Executive Director Appointment
Bright Minds Biosciences has appointed Dr. David Weiner as a non-executive director to its board, effective immediately. Dr. Weiner is a notable neuroscientist with over 25 years of experience, particularly in the development of novel therapeutics for neurological and psychiatric disorders. His appointment supports Bright Minds' transition from discovery to development, as well as compliance with Nasdaq's independent director requirements. The company has also granted stock options to consultants and a director as part of its share option plan.
Read more →DRUGNOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES Bright Minds Biosciences An
Bright Minds Biosciences has appointed Dr. David Weiner as a non-executive director to its board, enhancing its leadership with his extensive experience in neurosciences and psychedelics. This appointment supports the company's strategic shift from discovery to development, aiming to advance its innovative drug programs. Additionally, the company has regained compliance with Nasdaq governance requirements and granted stock options to key personnel as part of its share option plan. Dr. Weiner's background includes notable achievements in the development of therapeutics for neurological and psychiatric disorders.
Read more →DRUGBRIGHT MINDS BIOSCIENCES ANNOUNCES RECEIPT OF NASDAQ DEFICIENCY LETTER REGARDING INDEPENDENT DIRECTOR AND AUDIT COMMITTEE REQUIREMENTS Vancouver, British Columbia
Bright Minds Biosciences has received a deficiency letter from NASDAQ due to non-compliance with independent director and audit committee requirements. Following the resignation of Dr. Williamson, the company's board lacks the necessary majority of independent directors. Bright Minds has until July 10, 2023, to rectify this situation and is in discussions to appoint a new independent director. The company continues to focus on developing innovative treatments for neuropsychiatric disorders.
Read more →DRUGBright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements
Bright Minds Biosciences has received a Deficiency Letter from NASDAQ due to non-compliance with independent director and audit committee requirements following the resignation of Dr. Williamson. The board currently has only two independent directors out of four total, and the audit committee is similarly affected. However, the company has until July 10, 2023, to address this issue and is in advanced discussions to appoint a new independent director. Bright Minds focuses on innovative treatments for neuropsychiatric disorders and aims to regain compliance within the given timeline.
Read more →DRUGBright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
Bright Minds Biosciences Inc. has received a notification from NASDAQ regarding a deficiency related to the minimum bid price for its shares. The company has until July 25, 2023, to regain compliance, which can be achieved by maintaining a closing bid price of at least $1.00 for ten consecutive business days. Despite this notification, the shares will continue to trade on both the Canadian Securities Exchange and NASDAQ. Bright Minds focuses on developing treatments for neuropsychiatric disorders and aims to create safer and more effective drugs.
Read more →DRUGBRIGHT MINDS BIOSCIENCES ANNOUNCES RECEIPT OF NASDAQ NOTIFICATION LETTER REGARDING MINIMUM BID PRICE DEFICIENCY Vancouver, British Columbia
Bright Minds Biosciences Inc. received a notification letter from NASDAQ indicating its shares fell below the minimum closing bid price requirement of US$1.00 for thirty consecutive business days. The company has until July 25, 2023, to regain compliance by having a closing bid price above the threshold for at least ten consecutive days. Despite this notification, trading of its shares will continue as normal on both NASDAQ and the Canadian Securities Exchange. Bright Minds focuses on developing novel treatments for neuropsychiatric disorders and aims to resolve the compliance issue within the specified period.
Read more →DRUG▼ -7.5%on this news
Bright Minds Biosciences Announces Resignation of Board Member
Bright Minds Biosciences announced the resignation of Dr. Doug Williamson from its Board of Directors. Dr. Williamson has accepted a new full-time position that prevents him from continuing his role at Bright Minds. CEO Ian McDonald commended Dr. Williamson's scientific expertise, noting its importance in the company's drug development efforts for neuropsychiatric disorders. Bright Minds continues to focus on creating novel therapeutic treatments aimed at challenging brain conditions.
Read more →DRUG▼ -7.5%on this news
Bright Minds Biosciences Announces Resignation of Board Member Vancouver, BC
Bright Minds Biosciences announced the resignation of Dr. Doug Williamson from its Board of Directors, who accepted a full-time role elsewhere. The company's CEO expressed gratitude for Dr. Williamson's contributions, which were beneficial in advancing drug development for challenging brain disorders. Bright Minds remains dedicated to creating innovative therapeutics for neuropsychiatric conditions, with ongoing projects aimed at improving patient outcomes.
Read more →DRUGBright Minds Biosciences Announces Closing of Non-Brokered Private Placement
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DR
Read more →DRUGFiled by newsfilecorp.com THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. BRIGHT MINDS BI
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. BRIGHT MINDS BIOSCIENCES ANNOUNCES CLOSING OF NON-BROKERED Vancouver, British Columbia, December 2,
Read more →DRUG▲ +10.8%on this news
Bright Minds Biosciences Announces Non-Brokered Private Placement
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DR
Read more →DRUGBright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer -- Dr. Smith is a 20-year pharmaceutical industry veteran with extensive
Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer -- Dr. Smith is a 20-year pharmaceutical industry veteran with extensive central nervous system ("CNS") clinical development expertise -- Vancouver, BC - November 23,
Read more →DRUGBright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer
-- Dr. Smith is a 20-year pharmaceutical industry veteran with extensive central nervous system (“CNS”) clinical development expertise -- VANCOUVER, British Columbia, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRU
Read more →DRUGBright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR I
Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES VANCOUVER,
Read more →DRUGBright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES VANCOUVER, British Columbia, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright M
Read more →DRUG▼ -15.4%on this news· ran to -30% by day 1
Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome -- In predictive animal models, BMB-101 demonstrated significant reduction in both the
Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome -- In predictive animal models, BMB-101 demonstrated significant reduction in both the number and intensity of epileptic seizures -- Vancouver, BC - August 31, 2022 - Bright Minds
Read more →DRUG▼ -15.4%on this news· ran to -30% by day 1
Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome
VANCOUVER, British Columbia, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epileps
Read more →DRUG▼ -23.1%on this news· ran to -35% by day 1shared move
Bright Minds Biosciences Announces Closing of $4 Million Unit Offering
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DR
Read more →DRUG▲ +15.7%on this news· ran to -38% by day 3shared move
PROSPECTUS SUPPLEMENT DATED AUGUST 25, 2022 TO THE SHORT FORM BASE SHELF PROSPECTUS DATED JUNE 7, 2021 No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim othe
No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. This prospectus supplement, together with the short form base shelf prospectus dated June 7, 2021 (the "Base Prospectus") to which it relates, as amended or
Read more →DRUG▲ +48.9%on this news· ran to +122% by day 3shared move
Bright Minds Announces Pricing of Overnight Marketed Offering of Units
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (“Bright Minds” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focus
Read more →DRUG▼ -38.4%on this newsshared move
BRIGHT MINDS ANNOUNCES PRICING OF OVERNIGHT MARKETED OFFERING OF UNITS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. Vancouver, BC
BRIGHT MINDS ANNOUNCES PRICING OF OVERNIGHT MARKETED OFFERING OF UNITS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. Vancouver, BC - August 23, 2022 - Bright Minds Biosciences Inc. ("Bright Minds" or the "Company") (Nasdaq: DRUG)
Read more →DRUG▲ +72.8%on this news· ran to +131% by day 3shared move
BRIGHT MINDS ANNOUNCES OVERNIGHT MARKETED OFFERING OF UNITS THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINAT
BRIGHT MINDS ANNOUNCES OVERNIGHT MARKETED OFFERING OF UNITS THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. Vancouver, BC - August 22, 2022 - Bright Mind
Read more →DRUG▲ +72.8%on this news· ran to +131% by day 3shared move
Bright Minds Announces Overnight Marketed Offering of Units
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (“Bright Mind
Read more →DRUG▲ +121.4%on this newsshared move
Bright Minds Biosciences Comments on Recent Trading Activity Vancouver, BC
Bright Minds Biosciences Comments on Recent Trading Activity Vancouver, BC - August 18, 2022 - Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for targeted treatment of neurop
Read more →DRUG▲ +121.4%on this newsshared move
Bright Minds Biosciences Comments on Recent Trading Activity
VANCOUVER, British Columbia, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy an
Read more →DRUGBright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization
VANCOUVER, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epileps
Read more →DRUGBright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome -- Review of Phase I ready BMB-101 and upcoming milestones -- -- Webcast to be held on
Bright Minds Biosciences to Host Key Opinion Leader Symposium on -- Review of Phase I ready BMB-101 and upcoming milestones -- -- Webcast to be held on May 19, 2022, 4:00pm ET -- Vancouver, BC - May 12, 2022 - Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (
Read more →DRUGBright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome
-- Review of Phase I ready BMB-101 and upcoming milestones -- -- Webcast to be held on May 19, 2022, 4:00pm ET -- VANCOUVER, British Columbia, May 12, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biote
Read more →DRUGBright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties -- Herbert Y. Meltzer, MD; Karl Deisseroth, MD, PhD; Robe
Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties -- Herbert Y. Meltzer, MD; Karl Deisseroth, MD, PhD; Robert C. Malenka, MD, PhD; Michael P. Bogenschutz, MD; and Peter Hendricks,
Read more →DRUGBright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties
-- Herbert Y. Meltzer, MD; Karl Deisseroth, MD, PhD; Robert C. Malenka, MD, PhD; Michael P. Bogenschutz, MD; and Peter Hendricks, PhD, bring decades of clinical and research expertise in psychiatry, addiction, behavioral health, and pharmacology to guide Company’s development pro
Read more →DRUG▲ +8.4%on this news
Bright Minds Biosciences to Host Symposium on Therapeutic Developments with in Dravet Syndrome and Featuring a Panel with Key Opinion Leaders -- Review of Phase I ready BMB-101 and upco
Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders -- Review of Phase I ready BMB-101 and upcoming milestones -- -- Conference call to be held on May 19, 2022, 10:00am ET -- Vancouver, BC
Read more →DRUG▲ +8.4%on this news
Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders
-- Review of Phase I ready BMB-101 and upcoming milestones -- -- Conference call to be held on May 19, 2022, 10:00am ET -- VANCOUVER, British Columbia, April 19, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG
Read more →DRUGBright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial Vancouver, BC
Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial Vancouver, BC - March 14, 2022 - Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (Nasdaq: DRUG) (CSE: DRUG), a biotechnology c
Read more →DRUGBright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial
VANCOUVER, British Columbia, March 14, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilep
Read more →DRUGBright Minds Biosciences to Present at the Oppenheimer 32nd Annual Healthcare Conference Vancouver, BC
Bright Minds Biosciences to Present at the Oppenheimer 32nd Annual Healthcare Conference Vancouver, BC - March 8, 2022 - Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for th
Read more →DRUGBright Minds Biosciences to Present at the Oppenheimer 32nd Annual Healthcare Conference
VANCOUVER, British Columbia, March 08, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilep
Read more →DRUGBright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference Vancouver, BC
Bright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference Vancouver, BC - January 4, 2022 - Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targ
Read more →DRUGBright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference
VANCOUVER, British Columbia, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epileps
Read more →DRUGBright Minds Biosciences to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference
VANCOUVER, British Columbia, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epileps
Read more →DRUG▼ -8.4%on this news
Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT 2A Psychedelic Program for the Treatment of Mental Diseases - Hundreds of de novo patentable psychedelic-based compounds created through
Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases - Hundreds of de novo patentable psychedelic-based compounds created through discovery program - - Company plans to announce lead molecule in first
Read more →DRUG▼ -8.4%on this news
Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases
— Hundreds of de novo patentable psychedelic-based compounds created through discovery program — — Company plans to announce lead molecule in first quarter of 2022 — VANCOUVER, British Columbia, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” o
Read more →DRUGDATED NOVEMBER 3, 2021 For Immediate Release Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol "DRUG" Vancouver, BC
Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol "DRUG" Vancouver, BC - November 3, 2021 - Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for
Read more →DRUGBright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG”
VANCOUVER, British Columbia, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy an
Read more →DRUGFiled by newsfilecorp.com Bright Minds Biosciences to Present at the LD Micro Main Event Small Cap Investment Conference Vancouver, BC
Bright Minds Biosciences to Present at the LD Micro Main Event Small Cap Investment Conference Vancouver, BC - October 6, 2021 - Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel dru
Read more →DRUGBright Minds Biosciences to Present at the LD Micro Main Event Small Cap Investment Conference
VANCOUVER, British Columbia, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy an
Read more →DRUGFiled by newsfilecorp.com For Immediate Release Bright Minds Biosciences Provides Scientific Update -- Lead program, BMB-101, advances to IND-enabling toxicology studies with the aim of commencing human trials in 1H 2022
Bright Minds Biosciences Provides Scientific Update -- Lead program, BMB-101, advances to IND-enabling toxicology studies with the aim of commencing human trials in 1H 2022 -- Vancouver, BC -September 22, 2021 - Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company")
Read more →DRUGBright Minds Biosciences Provides Scientific Update
VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy a
Read more →DRUGFiled by newsfilecorp.com Bright Min ds Biosciences to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference; Shares Now Eligible for DTC Clearance VANCOUVER, British Columbia
Bright Minds Biosciences to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference; Shares Now Eligible for DTC Clearance VANCOUVER, British Columbia, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (
Read more →DRUGBright Minds Biosciences to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference; Shares Now Eligible for DTC Clearance
VANCOUVER, British Columbia, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy a
Read more →DRUGBright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonist Shows Significant Reduction in Seizure Activity
-- BMB proprietary 5-HT2C agonist, BMB-101, shows efficacy in pre-clinical models of Dravet Syndrome/Epilepsy, with lower seizure duration and frequency -- -- Effect of BMB compounds was consistent with other anti-epileptics such as fenfluramine -- VANCOUVER, British Columbia,
Read more →DRUGFiled by newsfilecorp.com For Immediate Release Bright Minds Biosciences ("BMB") Proprietary 5-HT 2C Agonist Shows Significant Reduction in Seizure Activity -- BMB proprietary 5-HT 2C agonist, BMB-101, shows efficacy in
Bright Minds Biosciences ("BMB") Proprietary 5-HT2C Agonist Shows Significant Reduction in Seizure Activity -- BMB proprietary 5-HT2C agonist, BMB-101, shows efficacy in pre-clinical models of Dravet Syndrome/Epilepsy, with lower seizure duration and frequency -- -- Effect of
Read more →DRUGBright Minds Biosciences Announces Application to List on Nasdaq
VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy, and
Read more →DRUGBright Minds Biosciences Appoints New Board Member and Expands Leadership Team
VANCOUVER, British Columbia, June 14, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pai
Read more →DRUGBright Minds Biosciences to Present at the H.C. Wainwright Virtual Conference Psychedelics in Psychiatry and Beyond
VANCOUVER, British Columbia, June 11, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pai
Read more →DRUGBright Minds Biosciences to Present at the 2021 LD Micro Invitational XI
VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pai
Read more →DRUGBright Minds Biosciences Shares to Commence Trading on the OTCQB Venture Market on May 17, 2021
VANCOUVER, British Columbia, May 17, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain
Read more →DRUGBright Minds Biosciences to Present at the Benzinga Global Small Cap Conference
VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announ
Read more →DRUGBright Minds Biosciences Appoints Industry Experts for Key Roles and Expands Scientific Advisory Team
VANCOUVER, British Columbia, April 27, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced two addition
Read more →DRUGBright Minds Biosciences Announces Closing of $25.9 Million Unit Offering
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, March 17, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:D
Read more →DRUGBright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonist Shows an Over 50% Decrease in Opioid Self-Administration in a Predictive Rodent Model
-- BMB compound significantly reduced fentanyl intake in an animal model of opioid abuse -- -- Potential to reduce continued opioid use in humans, a key treatment goal for opioid use disorder -- -- A brief virtual presentation discussing the findings is scheduled for Monday, Ma
Read more →DRUGBright Minds Biosciences to Present at the Stifel GMP Healthcare Conference - Healthcare Psychedelics: Addressing the Global Mental Health Crisis
VANCOUVER, British Columbia, March 10, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today anno
Read more →DRUGBright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonists Show Significant Reduction in Binge Eating
-- Model is predictive for human efficacy for binge eating -- -- BMB compound reduced binge eating in rats with a clear dose range for efficacy -- -- A virtual presentation discussing the findings is tentatively scheduled for Wednesday, March 10th at 11:00AM EST -- VANCOUVER,
Read more →DRUGBright Minds Biosciences Inc. Announces Pricing of Public Marketed Offering of Units
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DR
Read more →DRUGBright Minds Biosciences Inc. Announces Marketed Public Offering
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DR
Read more →DRUGBright Minds Biosciences Strengthens Scientific Advisory Team to Prepare for Future Growth
VANCOUVER, British Columbia, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds” or the “Company”), a biosciences company focused on creating the next generation of psychedelic and related therapies for the treatment of mental health and central nervous sys
Read more →DRUGBright Minds Biosciences Announces Listing on Canadian Stock Exchange
VANCOUVER, British Columbia, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds” or the “Company”), a biosciences company focused on creating the next generation of psychedelic and related therapies for the treatment of mental health and central nervous sys
Read more →Competitive Position
How DRUG ranks across every disease it competes inCompetitive Position is a premium feature
See how DRUG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial